ACR 2022 Tweet by Olga Petryna

#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo).